4-chloro-3-(difluoromethoxy)phenol | 1261440-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-chloro-3-(difluoromethoxy)phenol
• CAS: 1261440-11-2
• 化学式: C₇H₅ClF₂O₂
• 分子量: 194.565
• InChiKey: RLQNRFCWVMPJTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Chemical Compounds
  申请人：Bell Andrew Simon

  公开号：US20120010207A1

  公开（公告）日：2012-01-12

  The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar 1 , X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

  该发明涉及磺胺类衍生物，它们在医学上的应用，含有它们的组合物，用于它们的制备方法以及用于这些方法的中间体。更具体地，该发明涉及一种新的磺胺类Nav1.7抑制剂，其化学式为(I)：或其药用可接受的盐，其中Ar1、X、R1、R2、R3、R4和R5如描述中所定义。Nav1.7抑制剂在治疗各种疾病，特别是疼痛方面具有潜在的用途。
• N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS
  申请人：Pfizer Limited

  公开号：EP2593428A2

  公开（公告）日：2013-05-22
• SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN
  申请人：Pfizer Limited

  公开号：EP2593427A1

  公开（公告）日：2013-05-22
• US9096500B2
  申请人：——

  公开号：US9096500B2

  公开（公告）日：2015-08-04
• [EN] SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：PFIZER LTD

  公开号：WO2012007883A1

  公开（公告）日：2012-01-19

  The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I):or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.